On March 11, 2021, Kimera® Labs (https://kimeralabs.com/), one of the nation's top manufacturers of placental mesenchymal stem cell (pMSC) -derived exosomes, today announced the establishment of a novel and more relevant method to quantify and characterize exosomes - the Ross Unit (Ru), in an effort to standardize the measurement of nanovesicle technology. Kimera® Labs says it has established the Ru in order to rectify a misleading concept perpetuated by the tissue-banking industry that has correlated particle counts obtained by nano tracking analysis (NTA) to exosome concentration. In a novel approach to the subject, the Ru accounts solely for exosomal RNA cargo and protein concentration as opposed to gross quantification of all species (excipients) present in a solution. This scientifically valid process was developed by Kimera® Labs, Inc., and will be implemented in XoGlo® certificates of analysis in the first quarter of 2021. Kimera believes that the Ross Unit (Ru) describes a more accurate measurement of the purity and potency of exosome preparations and provides a reproducible method of therapeutic product characterization that will ultimately translate to improved patient outcomes. "When we debuted the Kimera® exosome product, XoGlo®, in 2014, we expended a significant amount of time and effort simply trying to communicate the concept of pMSC-derived paracrine effectors consisting of an invisible nanoparticle suspended in saline," said Duncan Ross PhD, and CEO of Kimera® Labs. "However, it was difficult to correlate the number of vesicles to the potency of a finished product.Login Or Register To Read Full Story